🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Assembly Biosciences, Inc. ASMB PHARMA

Healthcare · Biotechnology · United States
https://www.assemblybio.com
Company Profile ↓
$35.28
+42.55% 1Y
Mkt Cap$718.32M
P/E28.45
P/B2.13
52W High$38.50
52W Low$20.55
Book Value$15.40
EPS (TTM)$1.24

Company Overview

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Recent Developments

  • Dec 2025 Revenue of $72.30M (+153.5% YoY); net profit $-6.12M.
  • Trailing 12 Months Year-on-year growth — revenue +38.9%.
  • 5-Year Trend Long-term compounding — revenue CAGR -1.8%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-1.78%
1 Year:38.90%

Stock Price Performance

1 Year:+42.55%
6 Months:+21.11%
3 Months:+56.38%
1 Month:+32.23%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 82% of range
$20.55 $38.50
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • Golden Cross1d ago
  • RSI (14)61.60 · Neutral
Price Performance
1M+32.23%
3M+56.38%
6M+21.11%
1Y+42.55%
Valuation vs Sector

P/E of 28.45 is above the sector median of 24.83 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Revenue declined at -1.8% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
28.45
Industry PE
24.83
Forward P/E
-13.71
PEG Ratio
-
Book Value
$15.40
Price to Book
2.13
P/S
8.94
EV/EBITDA
-46.08
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-1.78%
Profit 5Y
-
Revenue (YoY)
38.90%
Earnings (YoY)
-

Profitability & Returns

ROCE
-5.80%
ROE
-0.03%
ROA
-2.67%
Profit Margin
-0.06%
Op Margin
-47.44%
Gross Margin
14.95%
EPS (Latest Qtr)
$-0.54
EPS (TTM)
$1.24

Balance Sheet & Liquidity

Debt/Equity
0.77
Quick Ratio
13.79
Current Ratio
13.99
Debt
$2.35M
Total Assets
$235.51M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
27.66%
Chg in Prom Hold
-0.76%
FII / Inst Holding
69.46%
Chg in FII Hold
0.01%

Financial Snapshot

Enterprise Value
$718.32M
Total Revenue (TTM)
$74.84M
EBITDA
$-8.69M
Free Cash Flow
$-27.87M
Operating Cash Flow
$-38.48M
Shares Outstanding
20.36M
Gross Margin
14.95%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ASMB Assembly Biosciences, Inc. PHARMA 35.28 28.45 $718.32M 0.00% -5.80% -0.03% -1.78% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026
Revenue ---------2.36M2.66M-3.56M3.22M4.29M-3.88M-----------------------
Operating Income -7.20M-7.15M-7.12M--11.28M-10.45M-11.68M--13.93M-13.57M-12.45M--16.67M-27.17M-22.57M--28.34M-19.70M-25.99M--27.69M6.58M-4.02M--27.26M-23.67M-18.88M-23.16M-24.57M-23.40M-19.56M-17.49M-15.05M-10.73M-12.20M-10.96M-9.94M-11.09M-10.88M-11.37M
Net Income -7.14M-6.94M-6.62M-7.75M-10.99M-10.15M-11.57M-11.55M-13.93M-13.60M-12.27M-3.01M-16.25M-26.81M-21.54M-26.16M-27.05M-18.50M-25.00M-27.08M-26.66M7.27M-3.35M-39.42M-27.20M-23.59M-18.80M-23.09M-24.46M-23.14M-18.95M-16.90M-14.42M-9.08M-11.15M-9.61M-8.82M-10.20M-9.20M-9.08M
Diluted EPS -------------0.80-1.30-0.87--1.05-0.72-0.96--0.760.19-0.09-1.11--0.55-0.41-0.48-0.51-0.48-4.46-3.88-3.29-1.66-1.98-1.51-1.17-1.33-0.72-0.54
R&D Expense 3.83M4.67M4.63M-8.12M7.52M8.83M-10.57M12.13M10.93M-14.54M17.84M19.11M-22.70M18.70M21.74M-23.05M23.33M26.94M-18.55M16.75M18.47M17.20M17.79M18.13M14.55M12.52M10.82M11.88M16.26M13.52M14.85M16.12M16.59M14.90M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue ---------09.02M14.80M15.96M79.11M6.25M07.16M28.52M72.30M
Operating Income ---3.34M-4.77M-34.00M-24.86M-19.60M-23.96M-29.66M-45.28M-52.23M-92.73M-102.71M-64.78M-132.69M-94.11M-64.65M-45.42M-12.12M
Net Income -4.57M-8.79M-4.54M-15.29M-34.34M-24.79M-19.40M-23.79M-28.45M-44.26M-42.81M-90.75M-97.63M-62.15M-129.85M-93.09M-61.23M-40.18M-6.12M
Diluted EPS ---------------3.00-23.08-13.38-6.69-0.55
R&D Expense --2.94M1.85M25.28M19.51M15.03M10.72M18.36M33.09M44.23M72.74M85.76M106.82M68.52M69.98M48.90M55.93M64.81M

Balance Sheet (Annual)

Figures in USD.

Metric Oct 2005Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets ----14.62M37.05M20.56M27.13M71.23M133.74M98.12M169.30M268.05M339.91M283.25M191.06M101.79M136.82M119.17M257.59M
Total Equity --4.38M-9.46M-13.36M11.63M34.53M17.81M24.49M58.57M118.74M79.88M113.12M210.65M273.22M240.58M168.93M82.66M41.10M33.36M206.75M
Cash & Equivalents 0-15.85K81.29K14.57M36.98M20.49M27.06M29.09M27.11M28.57M82.03M41.47M46.73M59.44M45.63M52.42M19.84M38.34M58.45M
Total Liabilities ----2.99M2.51M2.75M2.64M12.65M15.00M18.24M56.18M57.39M66.69M42.68M22.13M19.13M95.73M85.81M50.84M
Current Liabilities ----1.72M2.51M-2.64M1.05M3.40M7.12M13.49M18.47M24.44M24.43M16.07M16.30M39.23M47.80M48.78M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -3.48M-5.21M-25.07M-21.38M-17.80M-14.97M-18.70M-34.88M1.86M-64.96M-84.07M-62.96M-93.40M-84.46M22.74M-51.12M-41.09M
Investing Cash Flow ---11.96K-3.24K-6.48K277.40K-64.86M36.20M-15.64M-135.40M-50.32M68.07M26.52M90.64M-69.14M40.17M-113.47M
Financing Cash Flow 3.55M19.70M47.49M4.90M24.37M16.73M81.57M153.00K67.24M159.79M139.65M7.60M53.06M614.00K13.82M29.45M174.67M
Capital Expenditure -2.57K-0-11.96K-3.24K-6.48K-149.96K-58.26K-147.00K-865.00K-340.00K-1.55M-470.00K-3.10M-102.00K-255.00K-28.00K-66.00K
Free Cash Flow -3.49M-5.21M-25.08M-21.38M-17.80M-15.12M-18.76M-35.03M995.00K-65.30M-85.62M-63.43M-96.49M-84.56M22.49M-51.15M-41.16M

Ratios (Annual)

Figures in %.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -------------------
Operating Margin % -----------579.1%-626.4%-643.4%-81.9%-2,121.7%--902.5%-159.3%-16.8%
Net Margin % -----------474.7%-613.0%-611.6%-78.6%-2,076.4%--854.8%-140.9%-8.5%
ROE % 104.2%92.9%34.0%-131.5%-99.5%-139.2%-79.2%-40.6%-24.0%-55.4%-37.8%-43.1%-35.7%-25.8%-76.9%-112.6%-149.0%-120.4%-3.0%
ROCE % ----37.0%-98.5%--80.0%-34.1%-22.8%-49.8%-33.5%-37.2%-32.6%-25.0%-75.8%-110.1%-66.2%-63.6%-5.8%

Shareholding Pattern

Insiders
27.66%
Institutions
69.46%
Public Float
96.02%

Top Institutional Holders

#Holder% HeldSharesValue
1 Gilead Sciences Inc 24.44% 4.98M $124.28M
2 Farallon Capital Management LLC 7.88% 1.60M $40.07M
3 Paradigm Biocapital Advisors LP 7.63% 1.55M $38.80M
4 Commodore Capital Lp 6.95% 1.42M $35.33M
5 RA Capital Management, L.P. 5.01% 1.02M $25.48M
6 Jupiter Topco LLC 4.17% 849.31K $21.21M
7 Blackrock Inc. 3.77% 766.82K $19.15M
8 Parkman Healthcare Partners LLC 3.54% 721.18K $18.01M
9 Vanguard Capital Management LLC 2.75% 558.94K $13.96M
10 Point72 Asset Management, L.P. 2.26% 460.59K $11.50M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ASMB

Google News ue, 08 Sep 2026

A $75 million Gilead payment is due in Q4, while Assembly Bio expects cash to fund operations into 2029. - Stock Titan

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxPRF83cmUtVWNkNUNGTjVJSHBxYWxUMW83czlRbE9qcGh2VEFaakVSV3QtbklNM2VFd2I5alFST1UxU1hOOV8td1FRS1Jud21La1ZIQWNyX1ZSVklKZ3Y2bk8xTUZMbEZzZ2ZmazB0dXdjTm9UUWs5V3J4dzBGelJ0S2Z4c1hoeHMwMjFLaV…

Google News ue, 08 Sep 2026

Assembly Biosciences (ASMB) Shares U.S. Development Costs and Profits with Gilead on Herpes Treatment - gurufocus.com

<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxNX004dFJPTm9uUFVCRTc2VE4ybldGSkRBUUpvdnlzMjdfNE9SVEJWWVJEWXhtcTY3cWYtRldxTjFyTTY1UFJCbnBhbGZnTDBZYTkxNEFWQlBEdUprc1VYODV2TFNmaHlzNGU0cjFtRlQ5RGVlZEJNVktRV1Z6UVdQY3BXQXYzOVQ2bzFJSV…

Google News Mon, 07 Sep 2026

Wall Street Analysts See a 35.71% Upside in Assembly Biosciences (ASMB): Can the Stock Really Move This High? - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxQZTNVZjZhMGpUTVlLekJpVXVOYUk2bjYtYWRrWk1ZR2dUc0QteGRLbFNlU3FOaDUyR0dQczVYdEUxcWpfcGU1MW1Pc1RDazJiZE5Ja3VLWWNrNUVrTDhOVXFFS2c0WWUzTUFsUFpHMUpkVDEybzlJWGF5c1ZWaEUtOE1TcXhuMEtrcUtlbW…

Google News Fri, 04 Sep 2026

How Assembly Biosciences Inc. (ASMB) Affects Rotational Strategy Timing - Stock Traders Daily

<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxORDV1V3RGMTl1VGl5dzhwaWwzZU5GOWFRT2Y5Qk1mOUEtT2tReGxqNTNmZXZBRFlRRmcyVmRIalRMMl8wUW5kenJXTGcxbW1NZlVWb19na3IzR3VCdGlMNERQaVJoeEJsemJhNThmaXpFa2ZDODJRQm5lZ0VicDRZelBMYWl4NlJ2MmV0SG…

Google News Fri, 04 Sep 2026

5 Stocks With Recent Price Strength Buoyed by a Strong August - tradingview.com

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxPREpNVS1NZzBoVVFIMV9fZFRnN25OQ29UMDhGRzdBaElXUzROdHVjTkNUM2E2MThGZ0s4WFRfVTlhc0JzQXNwWjdERmN3R0dzVlFyWkVpcS16dDMteFVkZzhaZW82NUQwZVc2U09uM0U4NF82dG52TU9tQmVDUnlySkg3cHRLeEpuM2NUeW…

Google News Fri, 14 Aug 2026

Assembly Biosciences (ASMB) Stock Jumps As Losses Shrink And Revenue Builds - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxNZmdEVTV3N0dHSWJNM0ZzbURsSmo3dmdaNDBzVW93LUVYYldJRW9maXdHN1ZrdXBZQnNoSU5DZWVOOGl5TGJWTHZJckFjWno0T3BxX2d2M3JwLXRYN2JKRklfNGs1SklSVl8tTENaTVRhVFJLYnFLbXlVeWhfX1ZVN0ZvUUN0YW9tY0ZrQU…

ASMB — Frequently Asked Questions

What is the current share price of Assembly Biosciences, Inc. (ASMB)?

As of 2026-09-19 21:16 PDT, Assembly Biosciences, Inc. (ASMB) trades at $35.28 on NasdaqGS. Its 52-week range is $20.55 to $38.50.

What is the market capitalisation of ASMB?

Assembly Biosciences, Inc. (ASMB) has a market capitalisation of $718.32M on NasdaqGS.

What is the P/E ratio of ASMB?

ASMB trades at a trailing price-to-earnings (P/E) ratio of 28.45. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.13.

What is the return on equity (ROE) of ASMB?

ASMB has a return on equity (ROE) of -0.03%. Its return on capital employed (ROCE) is -5.80%.

Is ASMB a good stock to buy?

This page provides a data-driven analysis of Assembly Biosciences, Inc. (ASMB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space